Best-Link
Latest round
- Series C
Last raised
- May 2026
Total raised
- $88M
Investors
- 9
About Best-Link
Based in Shanghai, China and founded in 2021, Shanghai Best-Link Bioscience LLC, trading as Best-Link, focuses on the development of novel nano-conjugate drugs and precise nano-drug delivery platforms based on advanced conjugation technology and nanotechnology to develop innovative drugs for precision cancer treatment and tumor immunotherapy. It has submitted more than 10 invention patent applications through independent research and development as of 2023. The company is dedicated to creating a drug coupling platform and a drug precision delivery platform based on advanced drug linkage technology to develop innovative drugs for oncology precision therapy and oncology immunotherapy. The company's revenue is generated by providing nano-conjugate drugs.
Who invested in Best-Link
9 investors across 3 rounds
See all investors in Best-Link
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Best-Link
Who invested in Best-Link?
Best-Link has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Best-Link raised?
Best-Link has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Best-Link last raise money?
Best-Link's most recent round on record is a Series C, in May 2026.
What does Best-Link do?
Based in Shanghai, China and founded in 2021, Shanghai Best-Link Bioscience LLC, trading as Best-Link, focuses on the development of novel nano-conjugate drugs and precise nano-drug delivery platforms based on advanced conjugation technology and nanotechnology to develop innovative drugs for precision cancer treatment and tumor immunotherapy.
Where is Best-Link headquartered?
Best-Link is headquartered in Shanghai, China.
Which VCs invest in companies like Best-Link?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Best-Link's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Best-Link? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.